{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:04:03Z","timestamp":1794891843448,"version":"4.9.1"},"reference-count":98,"publisher":"American Society of Hematology","issue":"19","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,8]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>After successful efforts in adeno-associated virus (AAV) gene addition for hemophilia B gene therapy, the development of valoctocogene roxaparvovec (Roctavian; Biomarin) over the past decade represents a potential new hemophilia A (HA) treatment paradigm. Roctavian is the first licensed HA gene therapy that was conditionally approved in Europe in August 2022 and approved in the United States in June 2023. Beyond Roctavian, there are ongoing pivotal trials of additional AAV vectors for HA, others that are progressing through preclinical development or early-phase clinical trial, as well as non-AAV approaches in clinical development. This review focuses on the clinical development of Roctavian for which the collective clinical trials represent the largest body of work thus far available for any licensed AAV product. From this pioneering clinical development, several outstanding questions have emerged for which the answers will undoubtedly be important to the clinical adaptation of Roctavian and future efforts in HA gene therapy. Most notably, unexplained year-over-year declines in factor VIII (FVIII) expression after Roctavian treatment contrast with stable FVIII expression observed in other AAV HA gene therapy clinical trials with more modest initial FVIII expression. This observation has been qualitatively replicated in animal models that may permit mechanistic study. The development and approval of Roctavian is a landmark in HA therapeutics, although next-generation approaches are needed before HA gene therapy fulfills its promise of stable FVIII expression that normalizes hemostasis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011847","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T19:02:17Z","timestamp":1720724537000},"page":"5179-5189","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":53,"title":["Roctavian gene therapy for hemophilia A"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6772-4140","authenticated-orcid":false,"given":"Benjamin J.","family":"Samelson-Jones","sequence":"first","affiliation":[{"name":"1Clinical In Vivo Gene Therapy and Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA"},{"name":"2Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA"},{"name":"3Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana C.","family":"Small","sequence":"additional","affiliation":[{"name":"1Clinical In Vivo Gene Therapy and Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-1559","authenticated-orcid":false,"given":"Lindsey A.","family":"George","sequence":"additional","affiliation":[{"name":"1Clinical In Vivo Gene Therapy and Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA"},{"name":"2Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA"},{"name":"3Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"issue":"25","key":"2024100815203288000_bib1","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"2024100815203288000_bib2","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2024100815203288000_bib3","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024100815203288000_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024100815203288000_bib5","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024100815203288000_bib6","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024100815203288000_bib7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/hae.14936","article-title":"Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment","volume":"30","author":"Symington","year":"2024","journal-title":"Haemophilia"},{"key":"2024100815203288000_bib8","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1038\/ncomms3773","article-title":"Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A","volume":"4","author":"Du","year":"2013","journal-title":"Nat Commun"},{"issue":"1","key":"2024100815203288000_bib9","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1038\/s41467-022-30102-3","article-title":"Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates","volume":"13","author":"Milani","year":"2022","journal-title":"Nat Commun"},{"issue":"8","key":"2024100815203288000_bib10","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.ymthe.2017.04.029","article-title":"A\u00a0novel platform for immune tolerance induction in hemophilia A mice","volume":"25","author":"Merlin","year":"2017","journal-title":"Mol Ther"},{"issue":"11","key":"2024100815203288000_bib11","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/17474086.2023.2268279","article-title":"Looking to the future of gene therapy for hemophilia A and B","volume":"16","author":"Kaczmarek","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"21","key":"2024100815203288000_bib12","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024100815203288000_bib13","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/blood-2023-180803","article-title":"GO-8: stable expression of factor VIII over 5 years following adeno-associated gene transfer in subjects with hemophilia a using a novel human factor VIII variant","volume":"142","author":"Chowdary","year":"2023","journal-title":"Blood"},{"key":"2024100815203288000_bib14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-associated virus gene therapy for hemophilia","volume":"74","author":"Samelson-Jones","year":"2023","journal-title":"Annu Rev Med"},{"issue":"9","key":"2024100815203288000_bib15","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.2022018971","article-title":"Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1\/2 Alta study","volume":"143","author":"Leavitt","year":"2024","journal-title":"Blood"},{"issue":"17","key":"2024100815203288000_bib16","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2024100815203288000_bib17","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/mt.2009.35","article-title":"Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A","volume":"17","author":"Doering","year":"2009","journal-title":"Mol Ther"},{"issue":"18","key":"2024100815203288000_bib18","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1182\/blood.2020007562","article-title":"Activated protein C has a regulatory role in factor VIII function","volume":"137","author":"Wilhelm","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2024100815203288000_bib19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2023-178106","article-title":"Evolution directed gene engineering (EDGE) identifies single amino acid substitutions in FVIII with six-fold increased in\u00a0vitro and in\u00a0vivo activity","volume":"142","author":"Van Gorder","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2024100815203288000_bib20","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024100815203288000_bib21","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood-2022-170646","article-title":"Inhibiting APC cleavage of factor VIII for hemophilia A gene therapy","volume":"140","author":"Sternberg","year":"2022","journal-title":"Blood"},{"issue":"23","key":"2024100815203288000_bib22","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias--from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024100815203288000_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02383.x","article-title":"Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels","volume":"17","author":"den Uijl","year":"2011","journal-title":"Haemophilia"},{"issue":"23","key":"2024100815203288000_bib24","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1182\/bloodadvances.2023011366","article-title":"Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A","volume":"7","author":"Agosti","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"2024100815203288000_bib25","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024100815203288000_bib26","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024100815203288000_bib27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 6","key":"2024100815203288000_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"6","key":"2024100815203288000_bib29","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood.2019004334","article-title":"A\u00a0hemophilia A mouse model for the in\u00a0vivo assessment of emicizumab function","volume":"136","author":"Ferriere","year":"2020","journal-title":"Blood"},{"issue":"17","key":"2024100815203288000_bib30","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood-2016-02-683169","article-title":"Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project","volume":"129","author":"Manco-Johnson","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2024100815203288000_bib31","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jth.15182","article-title":"Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001-2018","volume":"19","author":"Hassan","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"8","key":"2024100815203288000_bib35","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1056\/NEJMe2212347","article-title":"Hemophilia A gene therapy - some answers, more questions","volume":"388","author":"George","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"2024100815203288000_bib36","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"2024100815203288000_bib37","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2024100815203288000_bib32","article-title":"Safety and efficacy of valoctocogene roxaparvovec in participants with active and prior FVIII inhibitors: preliminary results from GENEr8-INH, a phase 1\/2 study","author":"Young","year":"2024","journal-title":"Haemophilia"},{"issue":"8","key":"2024100815203288000_bib33","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/bloodadvances.2022008948","article-title":"Valoctocogene roxaparvovec gene transfer in participants with HIV","volume":"7","author":"Ragni","year":"2023","journal-title":"Blood Adv"},{"key":"2024100815203288000_bib34","article-title":"Safety and efficacy of valoctocogene roxaparvovec with prophylactic corticosteroids: 1-year GENEr8-3 results","volume":"30","author":"Ozelo","year":"2024","journal-title":"Haemophilia"},{"issue":"2","key":"2024100815203288000_bib38","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ymthe.2017.12.009","article-title":"Gene therapy with BMN 270 results in therapeutic levels of FVIII in mice and primates and normalization of bleeding in hemophilic mice","volume":"26","author":"Bunting","year":"2018","journal-title":"Mol Ther"},{"issue":"2","key":"2024100815203288000_bib39","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1128\/jvi.45.2.555-564.1983","article-title":"Nucleotide sequence and organization of the adeno-associated virus 2 genome","volume":"45","author":"Srivastava","year":"1983","journal-title":"J\u00a0Virol"},{"issue":"7-8","key":"2024100815203288000_bib40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1089\/hum.2022.050","article-title":"Human and insect cell-produced recombinant adeno-associated viruses show differences in genome heterogeneity","volume":"33","author":"Tran","year":"2022","journal-title":"Hum Gene Ther"},{"issue":"1","key":"2024100815203288000_bib41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/mt.2009.258","article-title":"Characterization of genome integrity for oversized recombinant AAV vector","volume":"18","author":"Dong","year":"2010","journal-title":"Mol Ther"},{"issue":"12","key":"2024100815203288000_bib42","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1016\/j.ymthe.2022.11.001","article-title":"Vector genome loss and epigenetic modifications mediate decline in transgene expression of AAV5 vectors produced in mammalian and insect cells","volume":"30","author":"Handyside","year":"2022","journal-title":"Mol Ther"},{"key":"2024100815203288000_bib43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.omtm.2020.05.018","article-title":"Methods matter: standard production platforms for recombinant AAV produce chemically and functionally distinct vectors","volume":"18","author":"Rumachik","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"7-8","key":"2024100815203288000_bib44","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/hum.2022.29207.wxi","article-title":"Recombinant adeno-associated virus production, the beginning of the end of uncertainty","volume":"33","author":"Xiao","year":"2022","journal-title":"Hum Gene Ther"},{"issue":"24","key":"2024100815203288000_bib45","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2015-10-675140","article-title":"Men with severe hemophilia in the United States: birth cohort analysis of a large national database","volume":"127","author":"Mazepa","year":"2016","journal-title":"Blood"},{"issue":"7-8","key":"2024100815203288000_bib46","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/hum.2021.287","article-title":"Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A","volume":"33","author":"Klamroth","year":"2022","journal-title":"Hum Gene Ther"},{"key":"2024100815203288000_bib47","author":"Sharma","year":"2022"},{"key":"2024100815203288000_bib48","author":"Harmon","year":"2023"},{"issue":"2","key":"2024100815203288000_bib49","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jth.13215","article-title":"A\u00a0critical appraisal of one-stage and chromogenic assays of factor VIII activity","volume":"14","author":"Peyvandi","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2024100815203288000_bib50","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40259-018-0261-x","article-title":"Codon optimization in the production of recombinant biotherapeutics: potential risks and considerations","volume":"32","author":"Mauro","year":"2018","journal-title":"BioDrugs"},{"issue":"22","key":"2024100815203288000_bib51","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1182\/blood.2020005683","article-title":"Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy","volume":"136","author":"Rosen","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2024100815203288000_bib52","article-title":"In\u00a0vitro and in\u00a0vivo models to understand one-stage and chromogenic factor VIII activity assay discrepancy of hepatocyte-derived factor VIII","volume":"5","author":"Sternberg","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2024100815203288000_bib53","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/jth.14343","article-title":"High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor","volume":"17","author":"Rietveld","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"issue":"8943","key":"2024100815203288000_bib54","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0140-6736(95)90166-3","article-title":"Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis","volume":"345","author":"Koster","year":"1995","journal-title":"Lancet"},{"issue":"6","key":"2024100815203288000_bib55","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2012.09134.x","article-title":"Elevated factor VIII levels and risk of venous thrombosis","volume":"157","author":"Jenkins","year":"2012","journal-title":"Br J Haematol"},{"issue":"1","key":"2024100815203288000_bib56","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-0037-1613748","article-title":"Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response","volume":"83","author":"O'Donnell","year":"2000","journal-title":"Thromb Haemost"},{"issue":"1","key":"2024100815203288000_bib57","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-0037-1613747","article-title":"High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism","volume":"83","author":"Kraaijenhagen","year":"2000","journal-title":"Thromb Haemost"},{"issue":"8","key":"2024100815203288000_bib58","doi-asserted-by":"crossref","first-page":"643","DOI":"10.7326\/0003-4819-130-8-199904200-00004","article-title":"Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism","volume":"130","author":"Rodeghiero","year":"1999","journal-title":"Ann Intern Med"},{"issue":"7","key":"2024100815203288000_bib59","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJM200008173430702","article-title":"High plasma levels of factor VIII and the risk of recurrent venous thromboembolism","volume":"343","author":"Kyrle","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024100815203288000_bib60","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/01.ATV.21.5.731","article-title":"Elevated factor VIII levels and the risk of thrombosis","volume":"21","author":"Kamphuisen","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2024100815203288000_bib61","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1046\/j.1365-2141.2000.02091.x","article-title":"Heritability of elevated factor VIII antigen levels in factor V Leiden families with thrombophilia","volume":"109","author":"Kamphuisen","year":"2000","journal-title":"Br J Haematol"},{"issue":"4","key":"2024100815203288000_bib62","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1182\/blood.V93.4.1271","article-title":"A\u00a0reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis","volume":"93","author":"de Visser","year":"1999","journal-title":"Blood"},{"issue":"12","key":"2024100815203288000_bib64","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1103\/PhysRevLett.86.2515","article-title":"Measurement of CP-violating asymmetries in B0 decays to CP eigenstates","volume":"86","author":"Aubert","year":"2001","journal-title":"Phys Rev Lett"},{"issue":"3","key":"2024100815203288000_bib65","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1-2 trial of AAVS3 gene therapy in patients with hemophilia B. Reply","volume":"387","author":"Chowdary","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"2024100815203288000_bib66","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.omtm.2020.07.005","article-title":"Induction of ER stress by an AAV5 BDD FVIII construct is dependent on the strength of the hepatic-specific promoter","volume":"18","author":"Fong","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"2024100815203288000_bib67","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med"},{"key":"2024100815203288000_bib68","unstructured":"Roctavian prescribing information. Vol. 2023. Accessed 5 February 2024. https:\/\/www.fda.gov\/media\/169937\/download?attachment: U.S. Food and Drug Administration."},{"key":"2024100815203288000_bib69","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013150","article-title":"Blood biodistribution and vector shedding of valoctocogene roxaparvovec in people with severe hemophilia A: results from the phase 3 GENEr8-1 trial","author":"Agarwal","year":"18  2024","journal-title":"Blood Adv"},{"issue":"1-2","key":"2024100815203288000_bib70","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41434-021-00287-1","article-title":"Ultra-sensitive AAV capsid detection by immunocapture-based qPCR following factor VIII gene transfer","volume":"29","author":"Sandza","year":"2022","journal-title":"Gene Ther"},{"issue":"1","key":"2024100815203288000_bib71","article-title":"Blood biodistribution and vector shedding of valoctocogene roxaparvovec in people with severe hemophilia A: results from the phase 3 GENEr8-1 trial","author":"Agarwal","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"2024100815203288000_bib72","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet"},{"issue":"6","key":"2024100815203288000_bib73","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1006\/mthe.2001.0494","article-title":"Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle","volume":"4","author":"Favre","year":"2001","journal-title":"Mol Ther"},{"issue":"6","key":"2024100815203288000_bib74","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ymthe.2006.03.002","article-title":"Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trial","volume":"13","author":"Schuettrumpf","year":"2006","journal-title":"Mol Ther"},{"issue":"17_suppl_2","key":"2024100815203288000_bib75","article-title":"Analysis of vector shedding following treatment with delandistrogene moxeparvovec (SRP-9001), an investigational rAAVrh74-based gene therapy for Duchenne muscular dystrophy (DMD)","volume":"100","author":"Malhotra","year":"2023","journal-title":"Neurology"},{"issue":"8","key":"2024100815203288000_bib76","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the state of the science for adeno-associated virus integration: an integrated perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol Ther"},{"issue":"4","key":"2024100815203288000_bib77","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/hae.14818","article-title":"Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis","volume":"29","author":"Astermark","year":"2023","journal-title":"Haemophilia"},{"key":"2024100815203288000_bib78","unstructured":"Agency GH. Comparative effectiveness of roctavian to standard of care hemostatic therapies in Germany among people with severe hemophilia A: a prospective non-interventional study utilizing data collected in the German hemophilia register. 2023. Accessed 5 February 2024. https:\/\/www.g-ba.de\/downloads\/40-268-9789\/2023-09-21_AM-RL-XII_Valoctocogen_2020-AbD-002_Studienprotokoll.pdf."},{"key":"2024100815203288000_bib79","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.omtm.2022.05.008","article-title":"Application of in-vitro-cultured primary hepatocytes to evaluate species translatability and AAV transduction mechanisms of action","volume":"26","author":"Liu","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"suppl 1","key":"2024100815203288000_bib80","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1182\/blood-2021-148661","article-title":"First-in-human dose-finding study of AAVhu37 vector-based gene therapy: BAY 2599023 has stable and sustained expression of FVIII over 2 year","volume":"138","author":"Pipe","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2024100815203288000_bib81","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A\u00a0long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2024100815203288000_bib82","doi-asserted-by":"crossref","first-page":"101205","DOI":"10.1016\/j.omtm.2024.101205","article-title":"AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of life","volume":"32","author":"Doshi","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2024100815203288000_bib83","doi-asserted-by":"publisher","DOI":"10.1101\/2024.05.16.594568","article-title":"Overcoming Hemophilia A gene therapy limitations with an enhanced function factor VIII variant","author":"Sternberg","year":"21  2024","journal-title":"bioRxiv"},{"issue":"1","key":"2024100815203288000_bib84","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1038\/s41467-023-38106-3","article-title":"The AAV capsid can influence the epigenetic marking of rAAV delivered episomal genomes in a species dependent manner","volume":"14","author":"Gonzalez-Sandoval","year":"2023","journal-title":"Nat Commun"},{"key":"2024100815203288000_bib85","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.omtm.2021.12.004","article-title":"Molecular analysis of AAV5-hFVIII-SQ vector-genome-processing kinetics in transduced mouse and nonhuman primate livers","volume":"24","author":"Sihn","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"2024100815203288000_bib86","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/mt.2009.280","article-title":"Little vector, big gene transduction: fragmented genome reassembly of adeno-associated virus","volume":"18","author":"Hirsch","year":"2010","journal-title":"Mol Ther"},{"issue":"21","key":"2024100815203288000_bib87","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/blood.2019002867","article-title":"Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum","volume":"135","author":"Poothong","year":"2020","journal-title":"Blood"},{"issue":"12","key":"2024100815203288000_bib88","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1016\/j.jtha.2023.10.005","article-title":"Cellular stress and coagulation factor production: when more is not necessarily better","volume":"21","author":"Chen","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"12","key":"2024100815203288000_bib89","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1016\/j.ymthe.2022.07.005","article-title":"IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia A mice","volume":"30","author":"Butterfield","year":"2022","journal-title":"Mol Ther"},{"key":"2024100815203288000_bib90","doi-asserted-by":"crossref","first-page":"16064","DOI":"10.1038\/mtm.2016.64","article-title":"Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice","volume":"3","author":"Lange","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2024100815203288000_bib91","doi-asserted-by":"crossref","first-page":"16063","DOI":"10.1038\/mtm.2016.63","article-title":"Potential for cellular stress response to hepatic factor VIII expression from AAV vector","volume":"3","author":"Zolotukhin","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2024100815203288000_bib92","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.omtm.2018.12.007","article-title":"Protein-engineered coagulation factors for hemophilia gene therapy","volume":"12","author":"Samelson-Jones","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"2024100815203288000_bib93","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy","volume":"24","author":"Louis Jeune","year":"2013","journal-title":"Hum Gene Ther Methods"},{"issue":"3","key":"2024100815203288000_bib94","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/hum.2017.094","article-title":"A\u00a0retrospective study of the cytokine profile changes in mice with FVIII inhibitor development after adeno-associated virus-mediated gene therapy in a hemophilia A mouse model","volume":"29","author":"Sun","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"1","key":"2024100815203288000_bib95","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/gt.2016.75","article-title":"Direct interaction of human serum proteins with AAV virions to enhance AAV transduction: immediate impact on clinical applications","volume":"24","author":"Wang","year":"2017","journal-title":"Gene Ther"},{"issue":"3","key":"2024100815203288000_bib96","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"issue":"2","key":"2024100815203288000_bib97","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ymthe.2020.12.008","article-title":"Early phase clinical immunogenicity of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A","volume":"29","author":"Long","year":"2021","journal-title":"Mol Ther"},{"issue":"9","key":"2024100815203288000_bib98","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol Ther"},{"issue":"4","key":"2024100815203288000_bib99","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/hae.14015","article-title":"World federation of hemophilia gene therapy registry","volume":"26","author":"Konkle","year":"2020","journal-title":"Haemophilia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/19\/5179\/2245452\/blooda_adv-2023-011847-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/19\/5179\/2245452\/blooda_adv-2023-011847-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T16:26:48Z","timestamp":1728404808000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/19\/5179\/516942\/Roctavian-gene-therapy-for-hemophilia-A"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":98,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,10,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011847","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]}}}